Return on Equity (ROE)
Updated 54h ago
Sector Performance
36th percentileMDT
9.8%
Sector Median
13.8%
Sector Avg
31.4%
Deep Analysis
Return on Equity (ROE) measures how efficiently a company generates profit from shareholders' money — a 9.8% ROE means MDT earns $0.098 for every dollar of equity.
That 9.8% sits below the sector median of 13.8%, placing MDT in the 36th percentile among its peers. No year-over-year, quarter-over-quarter, or eight-quarter trend data is available for this metric, with only a single current value of 9.8% reported. Without any trend direction, investors cannot determine whether ROE is improving or declining, which limits the ability to assess momentum. The combination of a below-median level and absent trend offers no clear signal for risk or opportunity, leaving an incomplete picture. This metric supports the overall NEUTRAL verdict because the below-average return is balanced by the absence of data showing deterioration, providing neither a clear positive nor negative case.
Frequently Asked Questions
What does the Return on Equity (ROE) tell investors about MDT?
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
How is the Return on Equity (ROE) calculated?
Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.
Who are MDT's closest peers by Return on Equity (ROE)?
The closest peers by Return on Equity (ROE) include: MRNA (-36.6%), FICO (-37.3%), XRAY (-37.7%), VRSN (-38.3%), MSCI (-45.3%).
The Formula
Net Income / Shareholders' Equity
Why It Matters
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
Master MDT's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full MDT research report →MDT
9.8%
Sector Median
13.8%
Sector Avg
31.4%
How MDT's Return on Equity (ROE) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.